# To Evaluate the Safety, Tolerability, PK, and PD of XW003 Injection in Healthy Adult Participants

> **NCT04389775** · PHASE1 · COMPLETED · sponsor: **Sciwind Biosciences APAC CO Pty. Ltd.** · enrollment: 64 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus
- Obesity
- Nonalcoholic Steatohepatitis

## Interventions

- **DRUG:** Cohort A
- **DRUG:** Placebo A
- **DRUG:** Cohort B
- **DRUG:** Placebo B

## Key facts

- **NCT ID:** NCT04389775
- **Lead sponsor:** Sciwind Biosciences APAC CO Pty. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-29
- **Primary completion:** 2021-09-29
- **Final completion:** 2021-09-29
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2021-10-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04389775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04389775, "To Evaluate the Safety, Tolerability, PK, and PD of XW003 Injection in Healthy Adult Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04389775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*